Tegafur
Teysuno (tegafur) is a small molecule pharmaceutical. Tegafur was first approved as Teysuno on 2011-03-14. It has been approved in Europe to treat stomach neoplasms.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
200 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 5 | 51 | 26 | 1 | 6 | 81 |
| Colorectal neoplasms | D015179 | — | — | 5 | 10 | 9 | 1 | 1 | 23 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 9 | — | 3 | 2 | 16 |
| Colonic neoplasms | D003110 | — | C18 | 2 | 5 | 2 | 1 | 4 | 12 |
| Neoplasms | D009369 | — | C80 | 4 | 5 | 1 | 1 | 1 | 11 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | 7 | 1 | 1 | — | 10 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 3 | 1 | 1 | — | 4 |
| Recurrence | D012008 | — | — | — | — | 1 | 1 | 1 | 3 |
| Microsatellite instability | D053842 | — | — | — | — | — | 1 | — | 1 |
| Maintenance chemotherapy | D060046 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenocarcinoma | D000230 | — | — | 2 | 19 | 7 | — | — | 27 |
| Carcinoma | D002277 | — | C80.0 | 2 | 17 | 3 | — | — | 22 |
| Squamous cell carcinoma | D002294 | — | — | — | 12 | 1 | — | — | 13 |
| Esophageal neoplasms | D004938 | — | C15 | — | 6 | 3 | — | 1 | 9 |
| Rectal neoplasms | D012004 | — | — | 3 | 5 | 1 | — | 2 | 9 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 4 | 3 | — | 1 | 8 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | — | 7 | 1 | — | — | 8 |
| Biliary tract neoplasms | D001661 | — | C24.9 | 1 | 4 | 2 | — | 1 | 7 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 3 | 1 | — | — | 6 |
| Neoadjuvant therapy | D020360 | — | — | — | 3 | 1 | — | 1 | 5 |
Show 11 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatocellular carcinoma | D006528 | — | C22.0 | 2 | 5 | — | — | — | 7 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 5 | — | — | — | 6 |
| Cholangiocarcinoma | D018281 | — | C22.1 | — | 1 | — | — | 3 | 4 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 2 | — | — | — | 3 |
| Bile duct neoplasms | D001650 | — | — | — | 1 | — | — | 1 | 2 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | 2 | — | — | — | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | 1 | — | — | 1 | 2 |
| Gallbladder neoplasms | D005706 | EFO_0004606 | C23 | — | 1 | — | — | 1 | 2 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | — | 1 | — | — | — | 1 |
| Unknown primary neoplasms | D009382 | — | — | — | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Small cell lung carcinoma | D055752 | — | — | 1 | — | — | — | — | 1 |
| Carcinoma in situ | D002278 | — | D09.9 | 1 | — | — | — | — | 1 |
| Survival rate | D015996 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tegafur |
| INN | tegafur |
| Description | Tegafur is a chemotherapeutic prodrug of 5-fluorouracil (5-FU) used in the treatment of cancers. It is a component of the combination drug tegafur/uracil. When metabolised, it becomes 5-FU.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=c1[nH]c(=O)n(C2CCCO2)cc1F |
Identifiers
| PDB | — |
| CAS-ID | 17902-23-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL20883 |
| ChEBI ID | 32188 |
| PubChem CID | 288216 |
| DrugBank | DB09256 |
| UNII ID | 1548R74NSZ (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 11,609 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,304 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use